TLPH Stock Summary and Trading Ideas (Talphera | NASDAQ:TLPH)

Talphera Inc. is a pharmaceutical company focused on the development and commercialization of therapies for use in medically supervised settings. The Company's nafamostat product candidates include Niyad and LTX-608. Its portfolio consists of nafamostat product candidates and pre-filled syringe product candidates.

Talphera trades on the NASDAQ stock market under the symbol TLPH.

As of April 2, 2026, TLPH stock price declined to $0.72 with 172,675 million shares trading.

TLPH has a beta of 0.61, meaning it tends to be less sensitive to market movements. TLPH has a correlation of 0.01 to the broad based SPY ETF.

TLPH has a market cap of $36.15 million. This is considered a Sub-Micro Cap stock.

The top ETF exchange traded funds that TLPH belongs to (by Net Assets): VXF.

TLPH has outperformed the market in the last year with a return of +36.3%, while the SPY ETF gained +18.2%. However, in the most recent history, TLPH shares have underperformed the stock market with its stock returning -36.6% in the last 3 month period and -6.3% for the last 2 week period, while SPY has returned -3.6% and -0.6%, respectively.

TLPH support price is $.74 and resistance is $.82 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that TLPH shares will trade within this expected range on the day.